Acquisition Announced

Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals

US$10bn equity value

Announced 6 Jul 2026 · NASDAQ: CRNX · US$85.00 cash per share

Advisers

Crinetics Pharmaceuticals

Target

Financial adviser
Fairness opinion

Vertex Pharmaceuticals Incorporated

Acquirer

Financial adviser
Legal adviser

Other advisers

Financial adviser
Target
Crinetics Pharmaceuticals
Acquirer
Vertex Pharmaceuticals Incorporated
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Pharma, Rare Disease

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.